Drs. Rosenberg and Morgans share their insights into 2 late‑breaking abstracts presented at ESMO 2023 on the first‑line treatment of metastatic urothelial carcinoma: EV‑302 on the combination of enfortumab vedotin and pembrolizumab and CheckMate 901 on the combination of nivolumab and gemcitabine/cisplatin.